Clinical Trials
4 trialsNCT04874194 2025-11-03
Omacetaxine and Venetoclax for the Treatment of Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome Harboring Mutant RUNX1
M.D. Anderson Cancer Center
Phase 1/2 Terminated
NCT02078960 2021-11-09
A Study to Evaluate the Pharmacokinetics, Safety,and Efficacy of Omacetaxine Given Subcutaneously as a Fixed Dose in Patients With Chronic Phase (CP) or Accelerated Phase (AP) Chronic Myeloid Leukemia (CML) (Referred to as the SYNSINCT Study)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 1/2 Terminated
NCT00004933 2016-07-04
Homoharringtonine Compared With Hydroxyurea for Chronic Myelogenous Leukemia That Has Not Responded to Interferon Alfa
Alliance for Clinical Trials in Oncology
Phase 3 Terminated
NCT00114959 2015-01-15
Homoharringtonine With Oral Gleevec in Chronic, Accelerated and Blast Phase Chronic Myeloid Leukemia (CML)
Teva Branded Pharmaceutical Products R&D, Inc.
Phase 2 Terminated